This trial is testing Avelumab as a possible treatment for endometrial cancer that has come back or spread. It will be tested alone and with Talazoparib or Axitinib.
2 Primary · 7 Secondary · Reporting Duration: 2 years
Experimental Treatment
105 Total Participants · 4 Treatment Groups
Primary Treatment: Avelumab · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: